Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases

Despite the increasing global incidence of brain disorders, achieving sufficient delivery towards the central nervous system (CNS) remains a formidable challenge in terms of translating into improved clinical outcomes. The brain is highly safeguarded by physiological barriers, primarily the blood-br...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release Vol. 366; pp. 519 - 534
Main Authors: Huang, Qianqian, Chen, Yongke, Zhang, Weiwei, Xia, Xue, Li, Hanmei, Qin, Meng, Gao, Huile
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01.02.2024
Subjects:
Blood-brain barrier
Brain
Brain Diseases - drug therapy
Brain targeting
Drug Delivery Systems
drugs
Humans
intranasal administration
nanomedicine
Nanotechnology
Nervous System Diseases
Neurological diseases
Nose
Nose-to-brain drug delivery
Neurological diseases
Brain targeting
Blood-brain barrier
Nanotechnology
Nose-to-brain drug delivery
ISSN:0168-3659, 1873-4995, 1873-4995
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the increasing global incidence of brain disorders, achieving sufficient delivery towards the central nervous system (CNS) remains a formidable challenge in terms of translating into improved clinical outcomes. The brain is highly safeguarded by physiological barriers, primarily the blood-brain barrier (BBB), which routinely excludes most therapeutics from entering the brain following systemic administration. Among various strategies investigated to circumvent this challenge, intranasal administration, a noninvasive method that bypasses the BBB to allow direct access of drugs to the CNS, has been showing promising results. Nanotechnology-based drug delivery systems, in particular, have demonstrated remarkable capacities in overcoming the challenges posed by nose-to-brain drug delivery and facilitating targeted drug accumulation within the brain while minimizing side effects of systemic distribution. This review comprehensively summarizes the barriers of nose-to-brain drug delivery, aiming to enhance our understanding of potential physiological obstacles and improve the efficacy of nasal delivery in future trials. We then highlight cutting-edge nanotechnology-based studies that enhance nose-to-brain drug delivery in three key aspects, demonstrating substantial potential for improved treatment of brain diseases. Furthermore, the attention towards clinical studies will ease the regulatory approval process for nasal administration of nanomedicines targeting brain disease. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0168-3659
1873-4995
1873-4995
DOI:10.1016/j.jconrel.2023.12.054